X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (220) 220
science & technology (201) 201
life sciences & biomedicine (200) 200
abridged index medicus (159) 159
general & internal medicine (134) 134
respiratory system (126) 126
critical care medicine (125) 125
evidence-based medicine (111) 111
united states (84) 84
risk factors (59) 59
practice guidelines as topic (54) 54
female (50) 50
male (42) 42
societies, medical (42) 42
fibrinolytic agents - therapeutic use (38) 38
middle aged (36) 36
care and treatment (35) 35
research (33) 33
diagnosis (32) 32
risk assessment (32) 32
adult (29) 29
cancer (29) 29
aged (28) 28
practice guidelines (27) 27
american heart association (26) 26
lung neoplasms - therapy (26) 26
cardiovascular system & cardiology (25) 25
antithrombotic therapy and prevention of thrombosis, 9th ed (24) 24
fibrinolytic agents - adverse effects (23) 23
lung neoplasms - pathology (23) 23
treatment outcome (22) 22
american college of chest physician evidence-based clinical practice guidelines online only (21) 21
antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physician evidence-based clinical practice guidelines online only articles (21) 21
pulmonary/respiratory (21) 21
cardiac & cardiovascular systems (20) 20
lung cancer (20) 20
thrombosis - drug therapy (20) 20
usage (20) 20
guidelines (19) 19
african americans (18) 18
cardiology (18) 18
thrombosis - prevention & control (18) 18
medicine & public health (17) 17
methods (17) 17
vitamin k - antagonists & inhibitors (17) 17
aspirin - therapeutic use (16) 16
cardiovascular disease (16) 16
neoplasm staging (16) 16
oncology (16) 16
quality of life (16) 16
dose-response relationship, drug (15) 15
lung neoplasms - diagnosis (15) 15
prevention (15) 15
analysis (14) 14
anticoagulants - administration & dosage (14) 14
clinical competence (14) 14
combined modality therapy (13) 13
continuing medical education (13) 13
fibrinolytic agents - administration & dosage (13) 13
platelet aggregation inhibitors - therapeutic use (13) 13
randomized controlled trials as topic (13) 13
adolescent (12) 12
anticoagulants - therapeutic use (12) 12
hemorrhage - chemically induced (12) 12
heparin - adverse effects (12) 12
heparin, low-molecular-weight - administration & dosage (12) 12
medical screening (12) 12
peripheral vascular disease (12) 12
thrombolytic therapy (12) 12
venous thromboembolism - prevention & control (12) 12
aspirin - administration & dosage (11) 11
carcinoma, non-small-cell lung - pathology (11) 11
child (11) 11
drug therapy, combination (11) 11
education, medical, continuing - standards (11) 11
evidence-based medicine - standards (11) 11
physicians (11) 11
practice guidelines as topic - standards (11) 11
thrombosis - blood (11) 11
united states - epidemiology (11) 11
american cancer society (10) 10
health aspects (10) 10
heparin, low-molecular-weight - therapeutic use (10) 10
international normalized ratio (10) 10
patients (10) 10
aged, 80 and over (9) 9
anticoagulants (9) 9
anticoagulants - adverse effects (9) 9
aspirin (9) 9
cough (9) 9
errata (9) 9
health care sciences & services (9) 9
heart (9) 9
hemorrhage - prevention & control (9) 9
heparin, low-molecular-weight - adverse effects (9) 9
medical societies (9) 9
medicine, general & internal (9) 9
patient selection (9) 9
platelet aggregation inhibitors - administration & dosage (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e44S - e88S
Background: The objective of this article is to summarize the published literature concerning the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently available for clinical use... 
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | United States | Humans | Pyridines - pharmacokinetics | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Dabigatran | Antithrombins - pharmacokinetics | Dose-Response Relationship, Drug | Rivaroxaban | Pyridines - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Benzimidazoles - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Benzimidazoles - adverse effects | Morpholines - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Benzimidazoles - pharmacokinetics | Anticoagulants - adverse effects | Evidence-Based Medicine | Factor Xa - metabolism | Thiophenes - pharmacokinetics | Vitamin K - blood | Antithrombins - adverse effects | Anticoagulants - pharmacokinetics | Thrombosis - drug therapy | Morpholines - pharmacokinetics | Practice Guidelines as Topic | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e24S - e43S
This article describes the pharmacology of approved parenteral anticoagulants. These include the indirect anticoagulants, unfractionated heparin (UFH),... 
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Heparitin Sulfate - adverse effects | United States | Humans | Thrombin - antagonists & inhibitors | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Dose-Response Relationship, Drug | Pipecolic Acids - administration & dosage | Chondroitin Sulfates - adverse effects | Societies, Medical | Pipecolic Acids - adverse effects | Heparitin Sulfate - administration & dosage | Polysaccharides - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Evidence-Based Medicine | Recombinant Proteins - administration & dosage | Antithrombins - agonists | Chondroitin Sulfates - administration & dosage | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Heparin, Low-Molecular-Weight - administration & dosage | Infusions, Intravenous | Practice Guidelines as Topic | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e89S - e119S
Journal Article
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e152S - e184S
Journal Article